Investment bank: Bavarian Nordic's RSV data reduces risk associated with important asset

Wednesday’s positive RSV vaccine candidate results from Bavarian Nordic could pave the way for positive dialog with possible partners before a phase III trial study begins, reads a comment from US-based investment bank Jefferies.

Photo: Bavarian Nordic / PR

Bavarian Nordic recently publicized positive results from a data study of its RSV vaccine candidate, MVA-BN RSV, which has shown a very good efficacy rate in its phase II study compared to the placebo.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs